Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) has been given an average recommendation of “Reduce” by the nine research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and eight have given a hold recommendation to the company.
Separately, Bank of America raised shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a report on Friday, September 6th.
View Our Latest Report on BAYRY
Bayer Aktiengesellschaft Stock Down 0.4 %
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.25 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.25. Bayer Aktiengesellschaft had a negative net margin of 2.74% and a positive return on equity of 16.96%. The company had revenue of $12 billion for the quarter. As a group, research analysts forecast that Bayer Aktiengesellschaft will post 1.38 EPS for the current fiscal year.
Bayer Aktiengesellschaft Company Profile
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Read More
- Five stocks we like better than Bayer Aktiengesellschaft
- What is an Earnings Surprise?
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- Ride Out The Recession With These Dividend Kings
- MarketBeat Week in Review – 9/30 – 10/4
- Compound Interest and Why It Matters When Investing
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.